# Prostate cancer Market > Prostate Cancer Market Research Report Information by Type (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy and Diagnosis), By End-User (Specialty Centers, Hospital & Clinics), and By Region (North America, Europe, Asia-Pacific, And Rest of The World) – Therapeutics Industry Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.62% - **2024:** $ 7.35 Billion - **2025:** $ 7.91 Billion - **2035:** $ 16.5 Billion - **Key Players:** AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Astellas Pharma (JP), Merck & Co. (US), Pfizer (US), Novartis (CH), Sanofi (FR), Amgen (US), Eli Lilly and Company (US) **Report ID:** MRFR/Pharma/1051-CR · **Pages:** 78 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580 --- ## Market Summary ## **Prostate Cancer Market Overview** As per MRFR analysis, the Prostate Cancer Market Size was estimated at 7.35 (USD Billion) in 2024. The Prostate Cancer Market Industry is expected to grow from 7.91 (USD Billion) in 2025 to 15.33 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.62% during the forecast period (2025 - 2034).There is a growing awareness among the general public about the importance of early diagnosis, which is driving demand for diagnostic tests. Improvements in technology, such as the development of new imaging techniques and biomarkers, are also contributing to the market growth of the prostate cancer diagnosis and therapy. **Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review** ## **Prostate Cancer Market Trends** Increased demand for certified prostate cancer diagnosis and therapy products to propel Advancements in diagnostic techniques, such as multiparametric  [magnetic resonance imaging](../../../reports/magnetic-resonance-imaging-systems-market-6194)  (mpMRI) and improved prostate-specific antigen (PSA) tests, have increased the accuracy of prostate cancer diagnosis, thus leading to a higher demand for prostate cancer diagnosis and therapy. The rising awareness regarding the early diagnosis and treatment of prostate cancer is also expected to fuel the market growth of prostate cancer diagnosis and therapy. Moreover, increasing investment in research and development activities, along with the launch of new and advanced products, is expected to create lucrative opportunities for market players. Thus, it is anticipated that this aspect will accelerate prostate cancer diagnosis and therapy market revenue Globally. The increasing awareness regarding prostate cancer and its treatments, as well as the launch of various campaigns by governments and non-profit organizations to increase awareness, is also expected to contribute to the prostate cancer diagnosis and therapy market's growth. For instance, September is designated as Prostate Cancer Awareness Month Globally to raise awareness about the significance of early detection and treatment of prostate cancer. This, in turn, is expected to increase the number of people getting screened and treated for prostate cancer, thereby driving the market growth of the prostate cancer diagnosis and therapy. The expansion of the prostate cancer treatment market is driven by factors such as a rise in the geriatric population, a rise in the prevalence of prostate cancer, an increase in generic products, a rise in awareness about treatment options, increased R&D investment by pharmaceutical companies, strong pipeline drugs, availability of new treatments, increase in demand for treatment and management, and increased use of hormonal agents in non-metastatic and metastatic cases. In addition, developing economies' untapped potential provides further market growth opportunities in the prostate cancer diagnosis and therapy during the forecast period. Thus, this factor is driving the market CAGR. ## **Prostate Cancer Market Segment Insights** ### **Prostate Cancer Diagnosis and Therapy Type Insights** The market segment of prostate cancer diagnosis and therapy, based on type, includes prostatic adenocarcinoma, and small cell carcinoma. The small cell carcinoma segment held the majority share in 2022 in the prostate cancer diagnosis and therapy market data. Small cell carcinoma is the most commonly used therapy for the treatment of prostate cancer, as it helps to shrink or slow down the growth of cancer by blocking the production or action of hormones that the cancer cells need to grow. [Chemotherapy](../../../reports/chemotherapy-market-5791) , biological therapy, and targeted therapy are also used to treat prostate cancer, depending on the stage and aggressiveness of cancer. **Figure 2:  Prostate cancer diagnosis and therapy Market, by Type, 2023 & 2030 (USD Billion)**  **Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review** ### **Prostate Cancer Diagnosis and Therapy Component Insights** The prostate cancer diagnosis and therapy market segmentation, based on component, includes therapy and diagnosis. The diagnosis segment dominated the market growth of prostate cancer diagnosis and therapy in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The improved understanding of the molecular mechanisms of prostate cancer and the identification of molecular markers that can guide therapy selection. A personalized medicine approach helps provide more effective and efficient treatment options, leading to improved patient outcomes. Additionally, the increasing availability of diagnostic tools and advances in technology are also driving the market growth of the prostate cancer diagnosis and therapy. ### **Prostate Cancer Diagnosis and Therapy End-User Insights** The market data of prostate cancer diagnosis and therapy, based on end-user, includes specialty centers, hospitals & clinics. The hospital & clinics segment dominated the market revenue of prostate cancer diagnosis and therapy in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Hospitals and clinics are the major end-users of prostate cancer diagnosis and therapy, accounting for a significant market share. However, the number of specialty centers is also growing and offering therapies for treating prostate cancer, contributing to the prostate cancer diagnosis and therapy market growth. ### **Prostate Cancer Diagnosis and Therapy Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America prostate cancer diagnosis and therapy market is expected to exhibit a significant CAGR growth during the study period. This is due to the high incidence of prostate cancer and increased awareness and research and development in the region. The approval of new drugs and treatments, such as the Pluvicto drug, and government support for innovation is expected to drive the market growth during the forecast period. Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3:  PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE BY REGION 2023 (%)**  **Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review** Europe market for prostate cancer diagnosis and therapy accounts for the second-largest market share. In Europe, the market for prostate cancer diagnosis and therapy are expected to grow significantly due to the increasing number of approvals for new drugs and therapies, a large patient population, and a well-established healthcare infrastructure. The high demand for advanced treatments and therapies is also a critical factor driving the market growth in this region. In addition, the increasing geriatric population and the high prevalence of prostate cancer in Europe are expected to drive the development of the region. Moreover, UK market of prostate cancer diagnosis and therapy held the largest market share, and the Germany market of prostate cancer diagnosis and therapy was the fastest growing market in the region. Asia Pacific market of prostate cancer diagnosis and therapy is expected to grow at the fastest CAGR from 2022 to 2030. In Asia-Pacific, the market of prostate cancer diagnosis and therapy are expected to grow significantly due to the increasing awareness about prostate cancer, the growing elderly population, and the increasing demand for advanced treatments and therapies. The increasing investments by government and private organizations in the healthcare sector, and the rising demand for advanced medical treatments, are expected to drive the market development in this region. Further, the China market of prostate cancer diagnosis and therapy held the largest market share, and the India market of prostate cancer diagnosis and therapy was the fastest growing market in the region. **Prostate Cancer Diagnosis and Therapy Key Market Players & Competitive Insights** Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of prostate cancer diagnosis and therapy even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the prostate cancer diagnosis and therapy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment. One of the primary business strategies adopted by manufacturers in the prostate cancer diagnosis and therapy industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, prostate cancer diagnosis and therapy industry has provided medicine with some of the most significant benefits. The prostate cancer diagnosis and therapy market major player such as Abbvie Inc., AstraZeneca, Bayer AG, Sanofi, IpsenPharma. RSIP Vision focuses on developing innovative solutions that improve the accuracy and efficiency of medical imaging, helping medical professionals make more informed diagnoses and treatment plans. By utilizing AI, deep learning, and computer vision technologies, RSIP Vision's solutions are designed to provide high-quality, actionable insights from medical images. RSIP Vision has launched a new tool for 3D reconstruction of the ureter. This technology transforms 2D fluoroscopic images into a medical-grade 3D model, which physicians can use for diagnosis, procedural planning, and real-time navigation during urologic procedures. Pfizer is one of the world's largest research-based pharmaceutical companies, with a focus on developing innovative solutions for the prevention and treatment of various diseases. It operates ly, with a portfolio of prescription medicines, vaccines, and consumer health products, aimed at improving the health and wellness of people around the world. Myovant Sciences, a clinical-stage biopharmaceutical company, partnered with Pfizer in January 2021 to commercialize its FDA-approved prostate cancer drug Orgovyx (relugolix). **Key Companies in the market of Prostate Cancer Diagnosis and Therapy includes** **Prostate Cancer Diagnosis and Therapy Industry Developments** **September 2023:** MDxHealth SA announced a partnership with Oxford University, whose aim is to study the relationship between Genomic Prostate Score (GPS) and test results post-treatment progression of this disease in men who have undergone various forms of localized prostate cancer therapy. **August 2023:** The U.S. Food and Drug Administration (FDA) granted approval to FoundationOneCDx as a [companion diagnostic](../../../articles/companion-diagnostics-market-outlook) of AKEEGA (abiraterone acetate Dual Action Tablet + niraparib) developed by Janssen Pharmaceuticals. This approval applies specifically to individuals with BRCA-positive metastatic castration-resistant prostate cancer. **July 2023:** A new biomarker test that identified prostate cancer using subspecialty pathology business was introduced by Quest Diagnostic called AmeriPath. The company signed a deal with Envision Sciences Pty Ltd., an Australian clinical diagnostics firm. **April 2022: ** As a part of the Milton and Carroll Petrie Department of Urology at Mount Sinai, a Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit was launched to address the disparity in prostate cancer outcomes for Black men and increase access to care. **March 2022: ** The approval of Pluvicto by the US FDA will allow Novartis to offer a new treatment option for adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, a variety of advanced prostate cancer. **March 2022:** Merck announced that they would be conducting a Keytruda plus Lynparza clinical trial targeting patients with metastatic-refractory prostate cancers that have keylynk-010. ## **Prostate Cancer Market Segmentation** ### **Prostate Cancer Diagnosis and Therapy Type Outlook  ** ### **Prostate Cancer Diagnosis and Therapy Component Outlook  ** ### **Prostate Cancer Diagnosis and Therapy End User Outlook ** ### **Prostate cancer diagnosis and therapy Regional Outlook** ## Market Drivers ### Rising Incidence of Prostate Cancer The Global Prostate Cancer Market Industry is experiencing growth due to the increasing incidence of prostate cancer worldwide. According to credible health statistics, prostate cancer is one of the most common cancers among men, with millions diagnosed annually. This rising prevalence is driving demand for innovative treatment options and diagnostic tools. As awareness increases, more men are seeking screening and treatment, contributing to the market's expansion. The projected market value of 7.35 USD Billion in 2024 underscores the urgency for effective solutions in managing this disease. ## Future Outlook The Prostate cancer Market is projected to grow at a 7.62% CAGR from 2025 to 2035, driven by advancements in diagnostics, treatment options, and increasing awareness. **New opportunities:** - Development of personalized immunotherapy treatments for advanced prostate cancer patients. Expansion of telehealth services for remote patient monitoring and consultations. Investment in AI-driven diagnostic tools to enhance early detection rates. By 2035, the Prostate cancer Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and technological advancements. ## Segment Insights ### By Diagnosis Method: Biopsy (Largest) vs. Blood Test (Fastest-Growing) The 'Diagnosis Method' segment in the prostate cancer market showcases a diverse distribution among its values, with biopsy emerging as the largest contributor. Biopsy holds a significant share of the market due to its established role as the gold standard in diagnosing prostate cancer. Following this are imaging methods, which aid in locating tumors, and the blood test segment, which is gaining traction as a less invasive option. Digital rectal examinations, while crucial in initial assessments, occupy a smaller share in comparison to these advanced techniques. Growth trends within this segment reveal that the blood test is the fastest-growing method, driven by advancements in technology that enable earlier detection and better monitoring of prostate cancer. Patients and healthcare providers are increasingly favoring blood tests due to their non-invasive nature and the growing awareness of prostate cancer. The biopsy continues to dominate, yet the shift towards less invasive methods reflects the evolving preferences within the healthcare landscape. Biopsy (Dominant) vs. Blood Test (Emerging) The biopsy method remains the dominant force in prostate cancer diagnosis, recognized for its accuracy and reliability in confirming cancer presence. This procedure increases physician confidence in diagnosis and treatment decisions, underpinning its widespread use. In contrast, the blood test is an emerging player, gaining momentum due to innovations such as the Prostate-Specific Antigen (PSA) test, which allows for a non-invasive approach. The growing preference for blood tests aligns with a shift towards personalized medicine, where early detection and monitoring become paramount. While biopsy will continue to be vital in definitive diagnosis, the emerging status of blood tests underscores an important trend towards patient-centric approaches in managing prostate cancer. ### By Treatment Type: Surgery (Largest) vs. Hormone Therapy (Fastest-Growing) In the Prostate cancer market, the treatment landscape is primarily dominated by surgery, which has established itself as the largest treatment option due to its effectiveness in localized cases. Following closely are radiation therapy and hormone therapy, with the latter emerging rapidly in recent years as a preferred choice for advanced cases. Chemotherapy also plays a role, particularly in metastatic scenarios, but largely in the later stages of treatment. The diverse therapeutic spectrum helps in catering to varying patient needs and preferences, thereby shaping the overall market dynamics. The growth trends within the Prostate cancer treatment segment are influenced by factors such as technological advancements in surgical techniques, increased awareness for early detection, and the evolving understanding of hormone therapy’s benefits. The shift toward personalized medicine is also propelling hormone therapy into a faster-growing position as clinicians increasingly adopt these approaches. Additionally, the rise in geriatric populations and lifestyle factors contributing to prostate cancer incidence are expected to drive continual demand across all treatment types, yet surgery remains a cornerstone treatment for many patients. Surgery (Dominant) vs. Hormone Therapy (Emerging) Surgery has long been the dominant form of treatment in the Prostate cancer market, primarily comprising radical prostatectomies and other surgical techniques. Its effectiveness in treating localized prostate cancer has established surgical intervention as the go-to approach for many healthcare professionals. The intricate nature of surgical procedures continues to evolve, with innovations like robotic-assisted surgeries enhancing precision and recovery times. On the other hand, Hormone Therapy emerges as a significant player in the treatment landscape, particularly for advanced prostate cancer. Its ability to target hormone-dependent tumors offers a unique therapeutic advantage, especially as it becomes increasingly recognized for its role in delaying disease progression. This growing awareness and its adaptability in combination therapies position Hormone Therapy as an essential complement to surgical interventions. ### By Stage of Cancer: Localized (Largest) vs. Metastatic (Fastest-Growing) In the Prostate cancer Market, the Localized stage holds the largest market share, reflecting its prevalence among diagnosed cases. This segment benefits from advancements in early detection and treatment options, leading to an increase in the number of patients diagnosed at this stage. Meanwhile, the Metastatic stage, while smaller, represents the fastest-growing segment as awareness rises regarding the disease's progression and the need for urgent treatment options. This growth is driven by both an increasing incidence of prostate cancer and advancements in therapeutic interventions. Growth trends within the Prostate cancer market indicate a shift towards more comprehensive treatment strategies across all stages. The Localized stage sees a continued investment in new therapies aimed at improving outcomes and reducing recurrence rates. In contrast, the Metastatic segment is experiencing heightened activity due to the rise in research for new targeted therapies and immunotherapeutics, addressing the urgent needs of patients with advanced disease. This dynamic has resulted in a market increasingly categorizing treatment approaches based on the stage of cancer, with ongoing innovations driving growth across the board. Localized (Dominant) vs. Metastatic (Emerging) The Localized stage of prostate cancer is characterized by its potential for high treatment success, as tumors are often confined to the prostate and can be effectively managed through surgery, radiation, or active surveillance. This segment benefits significantly from early detection programs, leading to better outcomes and a focus on preserving the patient's quality of life. As the dominant category, it not only represents a larger number of cases but also encourages ongoing research aimed at refining treatment methodologies. Conversely, the Metastatic stage, while considered emerging, is becoming increasingly prioritized in research and clinical settings. Patients diagnosed with metastatic prostate cancer often face more complex treatment regimens, including hormone therapy and chemotherapy. The rising incidence of advanced-stage diagnoses is propelling this segment forward, with innovation focusing on life-extending therapies and improving patient outcomes. This dynamic creates a compelling landscape where the prioritization of both stages drives growth and development in the overall prostate cancer market. ### By Patient Demographics: Age Group (Largest) vs. Ethnicity (Fastest-Growing) In the Prostate Cancer Market, the patient demographics segment illustrates a clear distribution of market share across various age groups and ethnicities. Age groups reveal a predominant share, particularly among men aged 65 and older, who represent the largest segment facing prostate cancer diagnoses. Ethnic diversity has surfaced as a significant factor, with African American men at a notably higher risk, thereby influencing treatment patterns and healthcare strategies. Age Group: 65+ (Dominant) vs. Ethnicity: African American (Emerging) The aged 65+ group is recognized as the dominant demographic in the Prostate Cancer Market, primarily due to the noticeable prevalence of prostate cancer in older men. This age group's health complications and increased screenings contribute to their larger market presence. Conversely, the African American demographic, while emerging, shows alarming rates of incidence and mortality associated with prostate cancer. This emerging group is gaining attention, spurring targeted outreach, and tailored treatment options to address the unique challenges faced by this population, highlighting an urgent need for focused intervention. ### By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing) The prostate cancer market shows significant distribution in healthcare settings, with hospitals holding the largest share due to their comprehensive treatment capabilities, advanced technology, and multidisciplinary approach to patient care. Outpatient clinics are gaining ground due to the increasing trend towards minimally invasive procedures and cost-effectiveness in treatment delivery, providing a more patient-centered approach that aligns with contemporary healthcare demands. Hospital (Dominant) vs. Outpatient Clinic (Emerging) Hospitals remain the dominant healthcare setting in the prostate cancer market, offering a wide range of diagnostic and treatment options including surgery, radiation therapy, and chemotherapy, supported by a multi-specialty team of oncologists and other healthcare professionals. In contrast, outpatient clinics are emerging as an essential component of care delivery, driven by the growing demand for convenient and accessible services, especially for follow-up care and routine management. They tend to focus on less invasive procedures and patient education, carving a niche for themselves as effective and efficient alternatives to traditional hospital settings. ## Regional Market Share Analysis ### North America : Market Leader in Prostate Cancer North America holds a significant share of the prostate cancer market, valued at $3.5 billion in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing awareness, and a rising incidence of prostate cancer. Regulatory support for innovative therapies and a strong focus on research and development further catalyze market expansion. The demand for effective treatment options continues to rise, supported by a growing aging population and improved screening methods. The competitive landscape in North America is robust, featuring key players such as AbbVie, Johnson & Johnson, and Merck & Co. These companies are at the forefront of developing novel therapies and maintaining a strong market presence. The U.S. is the leading country, contributing significantly to the market size, while Canada also plays a vital role in the regional dynamics. The presence of major pharmaceutical firms ensures a continuous flow of innovative treatments, enhancing patient outcomes. ### Europe : Emerging Market with Growth Potential Europe's prostate cancer market is valued at $2.0 billion, reflecting a growing demand for advanced treatment options. Factors such as increasing awareness, improved diagnostic techniques, and supportive healthcare policies are driving market growth. The region is witnessing a shift towards personalized medicine, with regulatory bodies encouraging the development of targeted therapies. The aging population and rising incidence of prostate cancer further contribute to the market's expansion. Leading countries in Europe include Germany, France, and the UK, which are home to several key players like Novartis and Sanofi. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms. The European Medicines Agency (EMA) plays a crucial role in regulating new therapies, ensuring safety and efficacy. This regulatory support fosters innovation and enhances the market's growth potential. ### Asia-Pacific : Rapidly Growing Market Segment The Asia-Pacific region's prostate cancer market is valued at $1.5 billion, driven by increasing awareness and advancements in healthcare infrastructure. The rising incidence of prostate cancer, coupled with a growing aging population, is propelling demand for effective treatment options. Regulatory bodies in countries like Japan and Australia are promoting research and development, which is crucial for market growth. The region is also witnessing a shift towards more personalized treatment approaches, enhancing patient outcomes. Key players in the Asia-Pacific market include Astellas Pharma and Pfizer, with Japan being a significant contributor to the market size. The competitive landscape is evolving, with both multinational corporations and local firms vying for market share. The presence of innovative therapies and a focus on improving healthcare access are essential for sustaining growth in this dynamic market. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa (MEA) prostate cancer market is valued at $0.35 billion, reflecting a nascent but growing segment. The market is driven by increasing awareness of prostate cancer and the need for improved healthcare services. However, challenges such as limited access to advanced treatments and varying healthcare infrastructure across countries hinder rapid growth. Regulatory bodies are beginning to focus on cancer treatment, which may catalyze future market expansion. Leading countries in the MEA region include South Africa and the UAE, where there is a growing presence of key players like Amgen and Eli Lilly. The competitive landscape is characterized by a mix of local and international firms, with efforts to enhance treatment accessibility. As healthcare systems evolve, the potential for growth in the prostate cancer market in this region is significant, albeit gradual. ## Competitive Benchmarking The Prostate cancer Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on personalized medicine. Major players such as AbbVie (US), Johnson & Johnson (US), and Merck & Co. (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. AbbVie (US) focuses on expanding its oncology portfolio through strategic acquisitions and collaborations, while Johnson & Johnson (US) emphasizes innovation in treatment modalities, particularly in immunotherapy. Merck & Co. (US) is leveraging its expertise in immuno-oncology to develop novel therapies, thereby shaping the competitive environment through a commitment to research and development.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The Prostate cancer Market appears moderately fragmented, with a blend of established pharmaceutical giants and emerging biotech firms. This structure allows for a diverse range of treatment options, although the influence of key players remains substantial, often dictating market trends and pricing strategies. In November AbbVie (US) announced a strategic partnership with a leading biotech firm to co-develop a novel prostate cancer therapy. This collaboration is poised to enhance AbbVie's research capabilities and accelerate the development of innovative treatment options, potentially positioning the company as a leader in the next generation of prostate cancer therapies. The strategic importance of this partnership lies in its potential to leverage combined expertise, thereby expediting the delivery of new therapies to market. In October Johnson & Johnson (US) launched a groundbreaking clinical trial for a new immunotherapy treatment aimed at advanced prostate cancer. This initiative underscores the company's commitment to pioneering innovative solutions that address unmet medical needs. The trial's success could significantly bolster Johnson & Johnson's market share and reinforce its reputation as a leader in oncology. In September Merck & Co. (US) unveiled a new digital health platform designed to enhance patient engagement and adherence to prostate cancer therapies. This initiative reflects a broader trend towards digitalization in healthcare, aiming to improve patient outcomes through technology. By integrating digital tools into its treatment protocols, Merck & Co. (US) is likely to enhance its competitive edge in a rapidly evolving market. As of December the Prostate cancer Market is witnessing a shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment development. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. The evolution of competitive differentiation appears to be moving away from price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains. This trend suggests that companies that prioritize research and development, alongside strategic partnerships, will likely emerge as leaders in the future. ## Recent News & Developments MDxHealth SA announced a partnership with Oxford University, whose aim is to study the relationship between Genomic Prostate Score (GPS) and test results post-treatment progression of this disease in men who have undergone various forms of localized prostate cancer therapy. **August 2023:** The U.S. Food and Drug Administration (FDA) granted approval to FoundationOneCDx as a [companion diagnostic](../../../articles/companion-diagnostics-market-outlook) of AKEEGA (abiraterone acetate Dual Action Tablet + niraparib) developed by Janssen Pharmaceuticals. This approval applies specifically to individuals with BRCA-positive metastatic castration-resistant prostate cancer. **July 2023:** A new biomarker test that identified prostate cancer using subspecialty pathology business was introduced by Quest Diagnostic called AmeriPath. The company signed a deal with Envision Sciences Pty Ltd., an Australian clinical diagnostics firm. **April 2022: ** As a part of the Milton and Carroll Petrie Department of Urology at Mount Sinai, a Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit was launched to address the disparity in prostate cancer outcomes for Black men and increase access to care. **March 2022: ** The approval of Pluvicto by the US FDA will allow Novartis to offer a new treatment option for adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, a variety of advanced prostate cancer. **March 2022:** Merck announced that they would be conducting a Keytruda plus Lynparza clinical trial targeting patients with metastatic-refractory prostate cancers that have keylynk-010. ## Report Scope | MARKET SIZE 2024 | 7.35(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.91(USD Billion) | | MARKET SIZE 2035 | 16.5(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.62% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Astellas Pharma (JP), Merck & Co. (US), Pfizer (US), Novartis (CH), Sanofi (FR), Amgen (US), Eli Lilly and Company (US) | | Segments Covered | Diagnosis Method, Treatment Type, Stage of Cancer, Patient Demographics, Healthcare Setting | | Key Market Opportunities | Advancements in precision medicine and biomarker discovery enhance treatment options in the Prostate cancer Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the prostate cancer treatment landscape. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Prostate cancer Market as of 2024?** A: The Prostate cancer Market was valued at 7.35 USD Billion in 2024. **Q: What is the projected market valuation for the Prostate cancer Market in 2035?** A: The market is projected to reach 16.5 USD Billion by 2035. **Q: What is the expected CAGR for the Prostate cancer Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Prostate cancer Market during 2025 - 2035 is 7.62%. **Q: Which companies are considered key players in the Prostate cancer Market?** A: Key players in the market include AbbVie, Bristol-Myers Squibb, Johnson & Johnson, and others. **Q: What are the primary diagnosis methods used in the Prostate cancer Market?** A: Primary diagnosis methods include Biopsy, Imaging, Blood Test, and Digital Rectal Examination. **Q: What is the market size for the Digital Rectal Examination segment in 2024?** A: The Digital Rectal Examination segment was valued at 2.85 USD Billion in 2024. **Q: How does the market for Hormone Therapy compare to other treatment types?** A: Hormone Therapy is projected to grow from 2.0 USD Billion to 5.0 USD Billion during the forecast period. **Q: What are the projected valuations for the Localized stage of cancer by 2035?** A: The Localized stage of cancer is expected to reach 5.5 USD Billion by 2035. **Q: What healthcare settings are included in the Prostate cancer Market analysis?** A: Healthcare settings include Hospital, Outpatient Clinic, and Home Care. **Q: What is the projected market size for Home Care in 2035?** A: The Home Care segment is projected to reach 5.0 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580*